The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to <i>CYP2C19</i> and <i>CYP3A5</i> genotypes

Abstract

The additive antiplatelet effect of cilostazol plus clopidogrel is maximized in subjects with both the CYP2C19 PM and CYP3A5*3/*3 genotypes because of a lack of change of clopidogrel thiol metabolite exposure in CYP3A5*3/*3 as well as the highest cilostazol IPA in CYP2C19 PM and CYP3A5*3/*3 subjects.